Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.

Sobrero, Alberto,
Maurel, Joan
Fehrenbacher, Louis
Scheithauer, Werner
Abubakr, Yousif,
Lutz, Manfred,
Vega-Villegas, M Eugenia
Eng, Cathy
Steinhauer, Ernst,
Prausova, Jana
Lenz, Heinz-Josef
Borg, Christophe
Middleton, Gary
Kröning, Hendrik
Luppi, Gabriele
Kisker, Oliver
Zubel, Angela
Langer, Christiane
Kopit, Justin
Burris, Howard,

May 2008

International audiencePURPOSE: To determine whether adding cetuximab to irinotecan prolongs survival...

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.

Sobrero, Alberto, F.
Maurel, Joan
Fehrenbacher, Louis
Scheithauer, Werner
Abubakr, Yousif, A.
Lutz, Manfred, P.
Vega-Villegas, M Eugenia
Eng, Cathy
Steinhauer, Ernst, U.
Prausova, Jana
Lenz, Heinz-Josef
Borg, Christophe
Middleton, Gary
Kröning, Hendrik
Luppi, Gabriele
Kisker, Oliver
Zubel, Angela
Langer, Christiane
Kopit, Justin
Burris, Howard, A.

May 2008

International audiencePURPOSE: To determine whether adding cetuximab to irinotecan prolongs survival...

First-line targeted therapies in the treatment of metastatic colorectal cancer &ndash; role of cetuximab

Giuseppe Tonini
Alice Calvieri
Bruno Vincenzi
Daniele Santini

April 2009

Giuseppe Tonini, Alice Calvieri, Bruno Vincenzi, Daniele SantiniMedical Oncology, University Campus ...

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

Maughan, Timothy S
Adams, Richard A
Smith, Christopher G
Meade, Angela M
Seymour, Matthew T
Wilson, Richard H
Idziaszczyk, Shelley
Harris, Rebecca
Fisher, David
Kenny, Sarah L
Kay, Edward
Mitchell, Jenna K
Madi, Ayman
Jasani, Bharat
James, Michelle D
Bridgewater, John
Kennedy, M John
Claes, Bart
Lambrechts, Diether
Kaplan, Richard
Cheadle, Jeremy P

June 2011

SummaryBackgroundIn the Medical Research Council (MRC) COIN trial, the epidermal growth factor recep...

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

Maughan, TS
Adams, RA
Smith, CG
Meade, AM
Seymour, MT
Wilson, RH
Idziaszczyk, S
Harris, R
Fisher, D
Kenny, SL
Kay, E
Mitchell, JK
Madi, A
Jasani, B
James, MD
Bridgewater, J
Kennedy, MJ
Claes, B
Lambrechts, D
Kaplan, R
Cheadle, JP

June 2011

BACKGROUND: In the Medical Research Council (MRC) COIN trial, the epidermal growth factor receptor (...

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

Maughan, TS
Adams, RA
Smith, CG
Meade, AM
Seymour, MT
Wilson, RH
Idziaszczyk, S
Harris, R
Fisher, D
Kenny, SL
Kay, E
Mitchell, JK
Madi, A
Jasani, B
James, MD
Bridgewater, J
Kennedy, MJ
Claes, B
Lambrechts, D
Kaplan, R
Cheadle, JP

January 2011

BACKGROUND: In the Medical Research Council (MRC) COIN trial, the epidermal growth factor receptor (...

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

Maughan, Timothyn S.
Adams, Richard A.
Smith, Chris
Meade, Angela M.
Seymour, Matthew T.
Wilson, Richard H.
Idziaszczyk, Shelley A.
Harris, Rebecca
Fisher, David
Kenny, Sarah L.
Kay, Edward
Mitchell, Jenna K.
Madi, Ayman
Jasani, Bharat
James, Michelle D.
Bridgewater, John
Kennedy, M. John
Claes, Bart
Lambrechts, Diether
Kaplan, Richard
Cheadle, Jeremy P.

June 2011

Background: In the Medical Research Council (MRC) COIN trial, the epidermal growth factor receptor (...

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

Maughan, Timothyn S.
Adams, Richard A.
Smith, Chris
Meade, Angela M.
Seymour, Matthew T.
Wilson, Richard H.
Idziaszczyk, Shelley A.
Harris, Rebecca
Fisher, David
Kenny, Sarah L.
Kay, Edward
Mitchell, Jenna K.
Madi, Ayman
Jasani, Bharat
James, Michelle D.
Bridgewater, John
Kennedy, M. John
Claes, Bart
Lambrechts, Diether
Kaplan, Richard
Cheadle, Jeremy P.

June 2011

Background: In the Medical Research Council (MRC) COIN trial, the epidermal growth factor receptor (...

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

Maughan, Timothyn S.
Adams, Richard A.
Smith, Chris
Meade, Angela M.
Seymour, Matthew T.
Wilson, Richard H.
Idziaszczyk, Shelley A.
Harris, Rebecca
Fisher, David
Kenny, Sarah L.
Kay, Edward
Mitchell, Jenna K.
Madi, Ayman
Jasani, Bharat
James, Michelle D.
Bridgewater, John
Kennedy, M. John
Claes, Bart
Lambrechts, Diether
Kaplan, Richard
Cheadle, Jeremy P.

June 2011

Background: In the Medical Research Council (MRC) COIN trial, the epidermal growth factor receptor (...

Allison L. Balko
Esther P. Black
Justin M. Balko

November 2015

Abstract: Metastatic colorectal cancer (mCRC) is primarily treated with cytotoxic chemotherapy. Howe...

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.

Sobrero, Alberto,
Maurel, Joan
Fehrenbacher, Louis
Scheithauer, Werner
Abubakr, Yousif,
Lutz, Manfred,
Vega-Villegas, M Eugenia
Eng, Cathy
Steinhauer, Ernst,
Prausova, Jana
Lenz, Heinz-Josef
Borg, Christophe
Middleton, Gary
Kröning, Hendrik
Luppi, Gabriele
Kisker, Oliver
Zubel, Angela
Langer, Christiane
Kopit, Justin
Burris, Howard,

May 2008

International audiencePURPOSE: To determine whether adding cetuximab to irinotecan prolongs survival...

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.

Sobrero, Alberto, F.
Maurel, Joan
Fehrenbacher, Louis
Scheithauer, Werner
Abubakr, Yousif, A.
Lutz, Manfred, P.
Vega-Villegas, M Eugenia
Eng, Cathy
Steinhauer, Ernst, U.
Prausova, Jana
Lenz, Heinz-Josef
Borg, Christophe
Middleton, Gary
Kröning, Hendrik
Luppi, Gabriele
Kisker, Oliver
Zubel, Angela
Langer, Christiane
Kopit, Justin
Burris, Howard, A.

May 2008

International audiencePURPOSE: To determine whether adding cetuximab to irinotecan prolongs survival...

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.

Sobrero, Alberto, F.
Maurel, Joan
Fehrenbacher, Louis
Scheithauer, Werner
Abubakr, Yousif, A.
Lutz, Manfred, P.
Vega-Villegas, M Eugenia
Eng, Cathy
Steinhauer, Ernst, U.
Prausova, Jana
Lenz, Heinz-Josef
Borg, Christophe
Middleton, Gary
Kröning, Hendrik
Luppi, Gabriele
Kisker, Oliver
Zubel, Angela
Langer, Christiane
Kopit, Justin
Burris, Howard, A.

May 2008

International audiencePURPOSE: To determine whether adding cetuximab to irinotecan prolongs survival...

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.

Sobrero, Alberto,
Maurel, Joan
Fehrenbacher, Louis
Scheithauer, Werner
Abubakr, Yousif,
Lutz, Manfred,
Vega-Villegas, M Eugenia
Eng, Cathy
Steinhauer, Ernst,
Prausova, Jana
Lenz, Heinz-Josef
Borg, Christophe
Middleton, Gary
Kröning, Hendrik
Luppi, Gabriele
Kisker, Oliver
Zubel, Angela
Langer, Christiane
Kopit, Justin
Burris, Howard,

May 2008

International audiencePURPOSE: To determine whether adding cetuximab to irinotecan prolongs survival...

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.

Sobrero, Alberto, F.
Maurel, Joan
Fehrenbacher, Louis
Scheithauer, Werner
Abubakr, Yousif, A.
Lutz, Manfred, P.
Vega-Villegas, M Eugenia
Eng, Cathy
Steinhauer, Ernst, U.
Prausova, Jana
Lenz, Heinz-Josef
Borg, Christophe
Middleton, Gary
Kröning, Hendrik
Luppi, Gabriele
Kisker, Oliver
Zubel, Angela
Langer, Christiane
Kopit, Justin
Burris, Howard, A.

May 2008

International audiencePURPOSE: To determine whether adding cetuximab to irinotecan prolongs survival...

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.

Sobrero, Alberto,
Maurel, Joan
Fehrenbacher, Louis
Scheithauer, Werner
Abubakr, Yousif,
Lutz, Manfred,
Vega-Villegas, M Eugenia
Eng, Cathy
Steinhauer, Ernst,
Prausova, Jana
Lenz, Heinz-Josef
Borg, Christophe
Middleton, Gary
Kröning, Hendrik
Luppi, Gabriele
Kisker, Oliver
Zubel, Angela
Langer, Christiane
Kopit, Justin
Burris, Howard,

May 2008

International audiencePURPOSE: To determine whether adding cetuximab to irinotecan prolongs survival...

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.

Sobrero, Alberto, F.
Maurel, Joan
Fehrenbacher, Louis
Scheithauer, Werner
Abubakr, Yousif, A.
Lutz, Manfred, P.
Vega-Villegas, M Eugenia
Eng, Cathy
Steinhauer, Ernst, U.
Prausova, Jana
Lenz, Heinz-Josef
Borg, Christophe
Middleton, Gary
Kröning, Hendrik
Luppi, Gabriele
Kisker, Oliver
Zubel, Angela
Langer, Christiane
Kopit, Justin
Burris, Howard, A.

May 2008

International audiencePURPOSE: To determine whether adding cetuximab to irinotecan prolongs survival...

First-line targeted therapies in the treatment of metastatic colorectal cancer &ndash; role of cetuximab

Giuseppe Tonini
Alice Calvieri
Bruno Vincenzi
Daniele Santini

April 2009

Giuseppe Tonini, Alice Calvieri, Bruno Vincenzi, Daniele SantiniMedical Oncology, University Campus ...

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

Maughan, Timothy S
Adams, Richard A
Smith, Christopher G
Meade, Angela M
Seymour, Matthew T
Wilson, Richard H
Idziaszczyk, Shelley
Harris, Rebecca
Fisher, David
Kenny, Sarah L
Kay, Edward
Mitchell, Jenna K
Madi, Ayman
Jasani, Bharat
James, Michelle D
Bridgewater, John
Kennedy, M John
Claes, Bart
Lambrechts, Diether
Kaplan, Richard
Cheadle, Jeremy P

June 2011

SummaryBackgroundIn the Medical Research Council (MRC) COIN trial, the epidermal growth factor recep...

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

Maughan, TS
Adams, RA
Smith, CG
Meade, AM
Seymour, MT
Wilson, RH
Idziaszczyk, S
Harris, R
Fisher, D
Kenny, SL
Kay, E
Mitchell, JK
Madi, A
Jasani, B
James, MD
Bridgewater, J
Kennedy, MJ
Claes, B
Lambrechts, D
Kaplan, R
Cheadle, JP

June 2011

BACKGROUND: In the Medical Research Council (MRC) COIN trial, the epidermal growth factor receptor (...

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

Maughan, TS
Adams, RA
Smith, CG
Meade, AM
Seymour, MT
Wilson, RH
Idziaszczyk, S
Harris, R
Fisher, D
Kenny, SL
Kay, E
Mitchell, JK
Madi, A
Jasani, B
James, MD
Bridgewater, J
Kennedy, MJ
Claes, B
Lambrechts, D
Kaplan, R
Cheadle, JP

January 2011

BACKGROUND: In the Medical Research Council (MRC) COIN trial, the epidermal growth factor receptor (...

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

Maughan, Timothyn S.
Adams, Richard A.
Smith, Chris
Meade, Angela M.
Seymour, Matthew T.
Wilson, Richard H.
Idziaszczyk, Shelley A.
Harris, Rebecca
Fisher, David
Kenny, Sarah L.
Kay, Edward
Mitchell, Jenna K.
Madi, Ayman
Jasani, Bharat
James, Michelle D.
Bridgewater, John
Kennedy, M. John
Claes, Bart
Lambrechts, Diether
Kaplan, Richard
Cheadle, Jeremy P.

June 2011

Background: In the Medical Research Council (MRC) COIN trial, the epidermal growth factor receptor (...

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

Maughan, Timothyn S.
Adams, Richard A.
Smith, Chris
Meade, Angela M.
Seymour, Matthew T.
Wilson, Richard H.
Idziaszczyk, Shelley A.
Harris, Rebecca
Fisher, David
Kenny, Sarah L.
Kay, Edward
Mitchell, Jenna K.
Madi, Ayman
Jasani, Bharat
James, Michelle D.
Bridgewater, John
Kennedy, M. John
Claes, Bart
Lambrechts, Diether
Kaplan, Richard
Cheadle, Jeremy P.

June 2011

Background: In the Medical Research Council (MRC) COIN trial, the epidermal growth factor receptor (...

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

Maughan, Timothyn S.
Adams, Richard A.
Smith, Chris
Meade, Angela M.
Seymour, Matthew T.
Wilson, Richard H.
Idziaszczyk, Shelley A.
Harris, Rebecca
Fisher, David
Kenny, Sarah L.
Kay, Edward
Mitchell, Jenna K.
Madi, Ayman
Jasani, Bharat
James, Michelle D.
Bridgewater, John
Kennedy, M. John
Claes, Bart
Lambrechts, Diether
Kaplan, Richard
Cheadle, Jeremy P.

June 2011

Background: In the Medical Research Council (MRC) COIN trial, the epidermal growth factor receptor (...

Allison L. Balko
Esther P. Black
Justin M. Balko

November 2015

Abstract: Metastatic colorectal cancer (mCRC) is primarily treated with cytotoxic chemotherapy. Howe...

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.

Sobrero, Alberto,
Maurel, Joan
Fehrenbacher, Louis
Scheithauer, Werner
Abubakr, Yousif,
Lutz, Manfred,
Vega-Villegas, M Eugenia
Eng, Cathy
Steinhauer, Ernst,
Prausova, Jana
Lenz, Heinz-Josef
Borg, Christophe
Middleton, Gary
Kröning, Hendrik
Luppi, Gabriele
Kisker, Oliver
Zubel, Angela
Langer, Christiane
Kopit, Justin
Burris, Howard,

May 2008

International audiencePURPOSE: To determine whether adding cetuximab to irinotecan prolongs survival...

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.

Sobrero, Alberto, F.
Maurel, Joan
Fehrenbacher, Louis
Scheithauer, Werner
Abubakr, Yousif, A.
Lutz, Manfred, P.
Vega-Villegas, M Eugenia
Eng, Cathy
Steinhauer, Ernst, U.
Prausova, Jana
Lenz, Heinz-Josef
Borg, Christophe
Middleton, Gary
Kröning, Hendrik
Luppi, Gabriele
Kisker, Oliver
Zubel, Angela
Langer, Christiane
Kopit, Justin
Burris, Howard, A.

May 2008

International audiencePURPOSE: To determine whether adding cetuximab to irinotecan prolongs survival...

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.

Sobrero, Alberto, F.
Maurel, Joan
Fehrenbacher, Louis
Scheithauer, Werner
Abubakr, Yousif, A.
Lutz, Manfred, P.
Vega-Villegas, M Eugenia
Eng, Cathy
Steinhauer, Ernst, U.
Prausova, Jana
Lenz, Heinz-Josef
Borg, Christophe
Middleton, Gary
Kröning, Hendrik
Luppi, Gabriele
Kisker, Oliver
Zubel, Angela
Langer, Christiane
Kopit, Justin
Burris, Howard, A.

May 2008

International audiencePURPOSE: To determine whether adding cetuximab to irinotecan prolongs survival...

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.

Sobrero, Alberto,
Maurel, Joan
Fehrenbacher, Louis
Scheithauer, Werner
Abubakr, Yousif,
Lutz, Manfred,
Vega-Villegas, M Eugenia
Eng, Cathy
Steinhauer, Ernst,
Prausova, Jana
Lenz, Heinz-Josef
Borg, Christophe
Middleton, Gary
Kröning, Hendrik
Luppi, Gabriele
Kisker, Oliver
Zubel, Angela
Langer, Christiane
Kopit, Justin
Burris, Howard,

May 2008

International audiencePURPOSE: To determine whether adding cetuximab to irinotecan prolongs survival...

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.

Sobrero, Alberto, F.
Maurel, Joan
Fehrenbacher, Louis
Scheithauer, Werner
Abubakr, Yousif, A.
Lutz, Manfred, P.
Vega-Villegas, M Eugenia
Eng, Cathy
Steinhauer, Ernst, U.
Prausova, Jana
Lenz, Heinz-Josef
Borg, Christophe
Middleton, Gary
Kröning, Hendrik
Luppi, Gabriele
Kisker, Oliver
Zubel, Angela
Langer, Christiane
Kopit, Justin
Burris, Howard, A.

May 2008

International audiencePURPOSE: To determine whether adding cetuximab to irinotecan prolongs survival...

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.

Sobrero, Alberto,
Maurel, Joan
Fehrenbacher, Louis
Scheithauer, Werner
Abubakr, Yousif,
Lutz, Manfred,
Vega-Villegas, M Eugenia
Eng, Cathy
Steinhauer, Ernst,
Prausova, Jana
Lenz, Heinz-Josef
Borg, Christophe
Middleton, Gary
Kröning, Hendrik
Luppi, Gabriele
Kisker, Oliver
Zubel, Angela
Langer, Christiane
Kopit, Justin
Burris, Howard,

May 2008

International audiencePURPOSE: To determine whether adding cetuximab to irinotecan prolongs survival...

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.

Sobrero, Alberto, F.
Maurel, Joan
Fehrenbacher, Louis
Scheithauer, Werner
Abubakr, Yousif, A.
Lutz, Manfred, P.
Vega-Villegas, M Eugenia
Eng, Cathy
Steinhauer, Ernst, U.
Prausova, Jana
Lenz, Heinz-Josef
Borg, Christophe
Middleton, Gary
Kröning, Hendrik
Luppi, Gabriele
Kisker, Oliver
Zubel, Angela
Langer, Christiane
Kopit, Justin
Burris, Howard, A.

May 2008

International audiencePURPOSE: To determine whether adding cetuximab to irinotecan prolongs survival...

First-line targeted therapies in the treatment of metastatic colorectal cancer &ndash; role of cetuximab

Giuseppe Tonini
Alice Calvieri
Bruno Vincenzi
Daniele Santini

April 2009

Giuseppe Tonini, Alice Calvieri, Bruno Vincenzi, Daniele SantiniMedical Oncology, University Campus ...

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

Abstract

Extracted data

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

Abstract

Extracted data

Related items

Related items